ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
41.10
1.11%
US Tech 100
20,873.20
0.19%
S&P 500
6,054.07
0.24%
US Dollar vs CAD
1.44109
0.07%
Bitcoin
105,978.19
2.16%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NovoCure Ltd (NVCR) Share Price

NovoCure Ltd

NovoCure Ltd (NVCR)

NASDAQ
25.80
0.28
( 1.10% )
Updated: 09:19:51
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
25.80
Bid
25.80
Ask
25.86
Volume
46,112
25.79 Day's Range 26.465
11.70 52 Week Range 34.13
Market Cap
2.792B
Previous Close
25.52
Open
25.97
Last Trade
1
@
25.83
Last Trade Time
09:20:35
Financial Volume
US$ 1,201,142
VWAP
26.0484
Average Volume (3m)
1,245,108
Shares Outstanding
108,201,434
Dividend Yield
-
PE Ratio
-13.49
Earnings Per Share (EPS)
-1.91
Revenue
509.34M
Net Profit
-207.04M

About NovoCure Ltd

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.novocure.com
Headquarters
Jersey, Gbr
Founded
-
NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NVCR. The last closing price for NovoCure was US$25.52. Over the last year, NovoCure shares have traded in a share price range of US$ 11.70 to US$ 34.13.

NovoCure currently has 108,201,434 shares outstanding. The market capitalization of NovoCure is US$2.76 billion. NovoCure has a price to earnings ratio (PE ratio) of -13.49.

Ask ADVFN Intelligence (AI)

NVCR Latest News

More News

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

New headquarters supports Novocure’s continued growth as it pursues its mission of extending survival in some of the most aggressive forms of cancer Novocure (NASDAQ: NVCR) announced today the...

January 22 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 15 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

January 13 2025
Edgar (US Regulatory)

Form 8-K - Current report

January 13 2025
Edgar (US Regulatory)

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST...

January 13 2025
Business Wire

Form 3 - Initial statement of beneficial ownership of securities

January 06 2025
Edgar (US Regulatory)

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive...

January 03 2025
Business Wire

Novocure annonce des résultats positifs de l'essai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs (TTFields) pour le cancer du pancréas

PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...

December 05 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.1-4.0892193308626.927.0324.9269273625.73270178CS
4-4.5795-15.074309978830.379531.1724.9296792427.44343912CS
127.893644.082562659217.906434.1315.35124510827.07099663CS
264.7422.507122507121.0634.1314.17115691422.07972208CS
5210.5669.291338582715.2434.1311.7127185719.2570719CS
156-37.91-59.504002511463.71120.0310.87110053237.18068071CS
260-60.19-69.996511222285.99232.7610.87100755666.12210617CS

NVCR - Frequently Asked Questions (FAQ)

What is the current NovoCure share price?
The current share price of NovoCure is US$ 25.80
How many NovoCure shares are in issue?
NovoCure has 108,201,434 shares in issue
What is the market cap of NovoCure?
The market capitalisation of NovoCure is USD 2.76B
What is the 1 year trading range for NovoCure share price?
NovoCure has traded in the range of US$ 11.70 to US$ 34.13 during the past year
What is the PE ratio of NovoCure?
The price to earnings ratio of NovoCure is -13.49
What is the cash to sales ratio of NovoCure?
The cash to sales ratio of NovoCure is 5.48
What is the reporting currency for NovoCure?
NovoCure reports financial results in USD
What is the latest annual turnover for NovoCure?
The latest annual turnover of NovoCure is USD 509.34M
What is the latest annual profit for NovoCure?
The latest annual profit of NovoCure is USD -207.04M
What is the registered address of NovoCure?
The registered address for NovoCure is NO 4 THE FORUM, GRENVILLE STREET, ST. HELIER, JERSEY, JE2 4UF
What is the NovoCure website address?
The website address for NovoCure is www.novocure.com
Which industry sector does NovoCure operate in?
NovoCure operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FOXXFoxx Development Holdings Inc
US$ 8.01
(177.16%)
410.96k
AMODAlpha Modus Holdings Inc
US$ 4.03
(161.69%)
61.67M
TECXTectonic Therapeutic Inc
US$ 50.285
(95.51%)
2.84M
KZIAKazia Therapeutics Ltd
US$ 2.41
(74.64%)
76.1M
ATHEAlterity Therapeutics Limited
US$ 4.35
(49.48%)
15.17M
CLEUChina Liberal Education Holdings Ltd
US$ 0.73
(-90.58%)
41.62M
CRGXCARGO Therapeutics Inc
US$ 3.11
(-76.42%)
9.03M
FATFAT Brands Inc
US$ 3.45
(-41.23%)
86.11k
SLXNSilexion Therapeutics Corporation
US$ 1.97
(-37.26%)
7.07M
KRKR36Kr Holdings Inc
US$ 6.21
(-34.08%)
471.36k
MGOLMGO Global Inc
US$ 0.1177
(15.73%)
107.91M
SPGCSacks Parente Golf Inc
US$ 0.86705
(46.96%)
78.25M
KZIAKazia Therapeutics Ltd
US$ 2.435
(76.45%)
76.14M
NVDANVIDIA Corporation
US$ 121.2982
(-1.94%)
65.73M
AMODAlpha Modus Holdings Inc
US$ 4.02
(161.04%)
61.68M

NVCR Discussion

View Posts
jondoeuk jondoeuk 3 weeks ago
KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.
👍️0
jondoeuk jondoeuk 3 weeks ago
Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma
👍️0
KIPK KIPK 3 weeks ago
dennisbabe - You are not smart enough to be impactful one way or another..
You are just one irrelevant poster.....
👍️0
KIPK KIPK 3 weeks ago
LOL - Garbage post....
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
thank you very much for sharing jondoeuk!
👍️0
jondoeuk jondoeuk 3 weeks ago
It is a pilot trial, but mPDAC is the largest category at diagnosis. Depending on the data (and if a pivotal trial ends up being successful), TTFs could eventually be used across all diagnosis categories.
👍️0
whosleftholdindabag whosleftholdindabag 4 weeks ago
Wishing a Happy New Year to everyone who is invested in $NVCR!
👍️0
KIPK KIPK 1 month ago
dennisdave, you & FeMike are made for each other. The two Irrelevant Scam Artistwannabies, begging for attention..

You are both piles of SSSSSSSSSSSSS.......HIT....
👍️0
KIPK KIPK 1 month ago
And you jondickuk, crawling around to save your clients from bad advise you capable of giving..

LOL....
👍️0
whosleftholdindabag whosleftholdindabag 2 months ago
$NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA
👍️0
PonkenPlonken PonkenPlonken 2 months ago
Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.
👍️0
jondoeuk jondoeuk 2 months ago
A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.

The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.
👍️0
whosleftholdindabag whosleftholdindabag 2 months ago
$NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA
👍️0
jondoeuk jondoeuk 2 months ago
Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
👍️ 1
tw0122 tw0122 2 months ago
Looking good $30 +
50% 
12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.
👍️0
PonkenPlonken PonkenPlonken 2 months ago
would love to see new session high
data is hot --- Can become SOC
👍️0
whosleftholdindabag whosleftholdindabag 2 months ago
$NVCR back above $20! GLTA
👍️0
Invest-in-America Invest-in-America 3 months ago
NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!
👍️ 1
jondoeuk jondoeuk 4 months ago
FDA Approves Novocure’s Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en
👍️ 1 💥 1
whosleftholdindabag whosleftholdindabag 4 months ago
Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 4 months ago
$NVCR great way to end the trading day! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 4 months ago
I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA
👍️0
KIPK KIPK 4 months ago
Glad to see you are in the right stock, NWBO, now!!
👍️0
TiltMyBrain TiltMyBrain 5 months ago
Who is the bag holder now???

Going to single digits
👍️ 1
whosleftholdindabag whosleftholdindabag 6 months ago
Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA
🚽 1
whosleftholdindabag whosleftholdindabag 6 months ago
Back above $20 $NVCR! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 8 months ago
Another week, another beautiful day for $NVCR shareholders! GLTA
🐀 1
whosleftholdindabag whosleftholdindabag 8 months ago
Another beautiful start of the week for $NVCR! GLTA
👍️0
KIPK KIPK 8 months ago
LOL - Go from over $200 to $20.
Wondering why this charity worker is NWBO hater.
Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...

BUT not this guy??

You judge!!!

KARMA!!
👍️ 3 💯 2
whosleftholdindabag whosleftholdindabag 9 months ago
GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 9 months ago
Beautiful day $NVCR! GLTA
👎️ 1 🤣 2
whosleftholdindabag whosleftholdindabag 9 months ago
It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA
👎️ 1 🚫 1 🤣 1
TiltMyBrain TiltMyBrain 9 months ago
Insiders to sell shares in 30 days
👍️ 2 💥 2
KIPK KIPK 9 months ago
LOL 🤣🤣🤣
👍️ 1 💯 1
dstock07734 dstock07734 9 months ago
Or you can simply wait.
👍️ 1 🤣 2
whosleftholdindabag whosleftholdindabag 9 months ago
Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA
🤣 1 ⚠️ 1
dstock07734 dstock07734 9 months ago
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
👍️ 3
dstock07734 dstock07734 9 months ago
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
👍️ 3 🤣 2
whosleftholdindabag whosleftholdindabag 9 months ago
No, do you? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 9 months ago
I'd be careful you're getting a wee bit close to libel don't you know? GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 9 months ago
Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 9 months ago
You're posting on the wrong board mate, $NWBO is the one dealing with toxic financers go over there and post your rubbish! GLTA

Streeterville Capital, LLC is a Chicago-based company owned by John M. Fife, who has been described as a "toxic lender" for many years. Toxic financing is a type of financing that companies use when they are in poor condition and can't get financing in any other way. It can come in the form of convertible debt or convertible preferred stock and often gives the debtholder an unlimited number of common shares when they convert their debt or preferred shares to common stock.
👍️ 1
TiltMyBrain TiltMyBrain 9 months ago
Toxic financing for a company who’s price is down 90% in last 3 years
👍️ 2 💥 2
TiltMyBrain TiltMyBrain 9 months ago
Today is the pump. Tomorrow is the insider dump
👍️ 2 💥 2
KIPK KIPK 9 months ago
What a great day right Nemeses 18?
How is dat charity holding da bag???
👍️ 1 😂 2 🤣 1
KIPK KIPK 9 months ago
Gone with the wind on wings of fake therapy IMO
👍️ 1 💯 1
KIPK KIPK 10 months ago
20? including a PRE-CLINICAL???? lol
And all that unfocused activity signal the total desperation to keep the SP up IMO...

Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
👍️0
axelvento axelvento 10 months ago
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
👎️ 2 🤣 1
TiltMyBrain TiltMyBrain 10 months ago
https://x.com/peter_brit/status/1775041789889491437?s=46&t=1nHn7IXseo2gJ7ymtRCgUA

This ship is sinking fast!
👍️ 3 👏 3
TiltMyBrain TiltMyBrain 10 months ago
insider selling in 3...2...1...
👍️ 3 💯 3 😂 1 🤣 1

Your Recent History

NASDAQ
NVCR
NovoCure
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads